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Abstract
Background: Chemotherapeutic agents have been associated with cardiotoxicity; thus, they require close monitoring. Several

echocardiographic variables have been investigated as early predictors of symptomatic cardiotoxicity in patients undergoing
chemotherapy.
Objective: To identify if global longitudinal strain (GLS) is a better predictor of symptomatic cardiotoxicity compared to left

ventricular ejection fraction (LVEF) in patients receiving chemotherapy.
Methods: MEDLINE, Scopus, and Cochrane Central Register of Controlled Trials were searched from inception through
December 2020. Adults who developed symptomatic cardiotoxicity (New York Heart Association [NYHA] Class III–IV heart failure,
cardiac arrest, or cardiac death) after undergoing chemotherapy with pre- and postchemotherapy echocardiographic measures of
cardiac function were included. The primary focus was on the prediction of symptomatic cardiotoxicity. Estimates were reported
as random effects hazard ratios (HR) with 95% confidence intervals (CI).
Results: Four studies met inclusion criteria. The most common malignancy identified in the included studies was breast cancer,

and the most common chemotherapeutic agent utilized was anthracyclines. Most studies utilized the Simpson biplane method to
measure echocardiographic parameters. Pooled results demonstrated no significant association between LVEF and the prediction
of symptomatic cardiotoxicity (HR 1.48; 95% CI, 0.96–2.27; P = 0.07). However, 2 studies that analyzed GLS found it to be a strong
predictor of symptomatic cardiotoxicity (HR 1.46; 95% CI, 1.34–1.58; P < .001). There was no significant association between
symptomatic cardiotoxicity and baseline left ventricular end diastolic volume, end systolic volume, or end diastolic volume index.
Conclusions: GLS may predict symptomatic cardiotoxicity and be used to monitor patients on chemotherapy for symptomatic
cardiac dysfunction. While the pooled results for baseline LVEF identified that it is not a predictor of symptomatic cardiotoxicity,
this differs from the findings of the only randomized trial included in this meta-analysis. The data for baseline GLS as a predictor
of symptomatic cardiotoxicity is encouraging, but definite evidence that GLS may be superior to LVEF is lacking. Prospective
randomized, blinded trials are required to identify if 1 echocardiographic parameter may be superior to the other.
Abbreviations: ASLS = average segmental longitudinal strain, CI = confidence intervals, GLS = global longitudinal strain,

HR = hazard ratio, LVEDV = left ventricular end-diastolic volume, LVEDVI = left ventricular end-diastolic volume index, LVEF =
left ventricular ejection fraction, LVESV = left ventricular end-systolic volume, LVESVI = left ventricular end-systolic volume index,
LVID = left ventricular internal diameter end diastole, LVIS = left ventricular internal diameter end-systole, MACE = major adverse
cardiac events, NYHA = New York Heart Association, OS = observational studies, PLS = peak longitudinal strain, PRISMA =
Preferred Reporting Items for Systematic Review and Meta-Analyses, RCT = randomized controlled trials.
Keywords: cardiotoxicity, chemotherapy, echocardiogram, ejection fraction, global longitudinal strain

candidates. Left ventricular ejection fraction (LVEF) is routinely
used to monitor cardiac function in patients undergoing chemotherapy.[2] However, various studies have shown that by the time
the LVEF is reduced, patients may have already suffered from
irreversible damage. Cardinale et al found that among patients
treated with anthracyclines and diagnosed with impairment

1. Introduction
In 2016, there were more than 10 million cancer survivors in
the United States, which is expected to double by 2026 approximately.[1] Certain chemotherapeutic agents are associated
with cardiotoxicity, which leads to their limited use in eligible
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Philadelphia, PA) Reference Manager, and duplicates were
removed. As this is a meta-analysis, this study did not require
approval by our institutional review board.

in LVEF, 36% of patients failed to recover to normal LV function, often despite therapeutic interventions.[3] Similarly, Tan et
al reported that among patients treated with anthracyclines,
taxanes, and trastuzumab, who developed LV dysfunction, the
abnormality generally persisted for greater than 2 years.[4]
There is a lack of consensus on how to define cardiotoxicity.
The American Society of Echocardiography defines cardiotoxicity as >10% decline in LVEF to a final value of <53% or >15%
relative decline in global longitudinal strain (GLS).[5] Whereas
the National Cancer Institute includes symptoms of LV dysfunction in their definition and divides the dysfunction into 5 grades,
with grade 2 suggesting mild heart failure symptoms and grade
5 involving death.[6] Once symptoms persist due to anthracycline-induced heart failure, the prognosis is poor, with <50%
survival at 1 year.[7] Thus, it has been proposed that merely
relying on LVEF may not identify the insidious remodeling that
results in symptomatic cardiotoxicity.[8] Studies have also suggested that myocardial deformation and GLS might be more
sensitive than LVEF and may be able to detect chemotherapy-induced symptomatic cardiotoxicity earlier.[9,10] Early reductions
in peak longitudinal strain (PLS) and strain rate while the LVEF
remains normal may predict further decreases in systolic function of the left ventricle.[11,12]
A recent meta-analysis by Oikonomou et al identified GLS as
having a good prognostic performance for subsequent cancer
therapy-related cardiac dysfunction.[13] However, Oikonomou et
al incorporated studies that included patients with both symptomatic and asymptomatic cardiotoxicity. It remains unclear
whether a drop in GLS among patients receiving chemotherapy
will predict eventual symptomatic cardiotoxicity. We, therefore,
conducted a systematic review and meta-analysis to identify
echocardiographic predictors of symptomatic cardiotoxicity
among chemotherapy patients to fill this knowledge gap.

2.2. Study selection
All citations were screened by 2 independent reviewers (MUS
and YY) based upon eligibility criteria. Inclusion criteria include
identifying adults who developed symptomatic cardiotoxicity
after undergoing chemotherapy with pre-and postchemotherapy
echocardiographic measures of cardiac function. Symptomatic
cardiotoxicity was defined by the presence of signs and New
York Heart Association (NYHA) Class III-IV symptoms of congestive heart failure (shortness of breath, swelling, paroxysmal
nocturnal dyspnea), cardiac arrest, or cardiac death. No restrictions to the type of malignancy were placed. Studies that did not
report the relation of echocardiographic measures to cardiotoxicity were excluded. nonrelevant citations were excluded based
on title and abstract. Abstracts, case reports, and editorials were
also excluded. Both randomized controlled trials (RCTs) and
observational studies (OS) were included. Any disagreements
between the 2 investigators were resolved by consensus of the
study group.
2.3. Data extraction and risk of bias
Two independent reviewers (MUS and YY) extracted the data
regarding the year of publication, sample size, study design,
baseline patient profiles, echocardiographic parameters, type of
malignancy, type of chemotherapy agent, and follow-up time
using a standardized data extraction form. Echocardiographic
parameters included were GLS, LVEF, left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic volume
index (LVEDVI), left ventricular end-systolic volume (LVESV),
left ventricular end-systolic volume index (LVESVI), and average segmental longitudinal strain. The risk of bias was assessed
using the Cochrane risk of bias tools for RCTs and SIGN methodology for observational studies. Each potential source of bias
was graded as high, low, or unclear.

2. Methods
2.1. Data sources and search strategy
According to the Preferred Reporting Items for Systematic
Review and Meta-Analyses (PRISMA) guidelines, this systematic review and meta-analysis was reported.[14] Medline,
Scopus, and Cochrane Central Register of Controlled Trials
were searched from database inception through December
2020 using the following combination of keywords:
Echocardiography OR global longitudinal strain OR left ventricular function OR myocardial strain OR echocardiographic
characteristics AND chemotherapy OR anthracyclines AND
left ventricular dysfunction OR myocardial ischemia OR myocardial infarction OR cardiac events OR cardiac death OR
heart failure. No time restriction was placed on the search;
however, the language was restricted to English. Online libraries including www.clinicaltrialresults.org, www.clinicaltrials.
gov, abstracts, and presentations from major cardiovascular
proceedings were also searched to identify gray literature. The
Supplementary Material (Supplemental Figure 1, http://links.
lww.com/MD/G899) outlines a complete description of the
search strategy. All citations retrieved from the search were
transferred to EndNote X7.5 (Thompson ISI ResearchSoft,

2.4. Statistical analysis
Outcomes from each study were pooled and compared using a
random-effects model to account for potential between-study
variance. The treatment effect was reported as hazard ratios
(HR) with 95% confidence intervals (CI). The I2-statistic was
quantified to measure heterogeneity, with values >25%, 50%,
and 75% consistent with low, moderate, and high degrees of
heterogeneity, respectively.[15] Review Manager Software v5.3
was used for all analyses. Publication bias was not assessed
since the number of studies was low (<10). P values <0.05
were considered statistically significant. Certainty in the evidence (i.e., confidence in the final estimates) was assessed
using the GRADE approach (Grades of Recommendation,
Assessment, Development, and Evaluation) based on the risk
of bias, imprecision, indirectness, inconsistency, and publication bias.[16]
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3. Results
Of 708 unique articles screened, 4 studies were included in the
analysis. The systematic review and study selection are outlined in the PRISMA flow chart (Fig. 1). Among the 4 included
studies, only 1 was an RCT. A summary of the included studies
is shown in Table 1. The mean follow-up period was 7.3 years.
The most common echocardiographic parameter measured
was LVEF. The baseline LVEF in patients with and without
symptomatic cardiotoxicity was >50%. The baseline GLS for
patients with symptomatic cardiotoxicity varied from –15 to
–16, whereas the baseline GLS in patients without symptomatic cardiotoxicity varied from –17.8 to –19.7. Supplemental
Table 1, http://links.lww.com/MD/G899 and Figure 2 show
the risk of bias assessment, and all studies had a low risk
of bias overall. However, the risk of selection bias was high
among OS due to a lack of randomization. Similarly, the risk
of performance bias was high among OS due to a lack of
blinding.

could be used to predict cardiotoxicity in patients receiving
chemotherapy.[17,18] Two studies did not show any significant
relationship between LVEF and prediction of symptomatic cardiotoxicity (Supplemental Table 2, http://links.lww.com/MD/
G899).[9,19]
The pooled analysis did not demonstrate any significant association between LVEF and prediction of symptomatic cardiotoxicity (HR 1.48; 95% CI, 0.96–2.27; P = .07). The I2 value
was 97%, indicating an increased level of heterogeneity among
the studies (Fig. 3).
The sensitivity analysis of the pooled findings after the exclusion of the RCT data conducted by Pivot et al showed results
consistent with the overall HR of the baseline LVEF (1.80,
95% CI 0.80–1.35) (Fig. 3).[18] Interestingly, when evaluated
individually, the trial conducted by Pivot et al was significant
for baseline LVEF as a predictor of symptomatic cardiotoxicity.
This is likely due to a lower baseline LVEF (50–59%) of the
participants in the study and the addition of trastuzumab to
anthracyclines for the treatment of breast cancer, which in itself
is cardiotoxic.[20]

4. Predictors of symptomatic cardiotoxicity

4.2. Baseline global longitudinal strain

3.1. Baseline demographics

Two studies reported baseline GLS prior to initiating chemotherapy.[9,19] Both studies found GLS to be a significant predictor
of symptomatic cardiotoxicity in patients receiving chemotherapy. Data for meta-analysis was pooled from the 2 studies. The
meta-analysis demonstrated a significant association between

4.1. Baseline left ventricular ejection fraction
All 4 trials analyzed LVEF as a predictor of symptomatic cardiotoxicity. The Simpson biplane method was the most utilized
technique to measure LVEF. Two studies reported that LVEF

Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of the included studies.
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Patients with hematologic cancers treated with anthracycline who
underwent prechemotherapy echocardiography/ Baseline LVEF:
62 (No MACE), 58 (MACE) & GLS: -19.7 (No MACE), -15 (MACE)
Patients treated with anthracyclines with a baseline LVEF between
50 and 59% by 2D echocardiography/Baseline LVEF: 54 (No
MACE), 53 (MACE) & GLS: -17.8 (No MACE), -16 (MACE)
12- to 6-months of trastuzumab given either concomitantly or
sequentially after standard (neo)-adjuvant chemotherapy in
women with HER2-positive early breast cancer/ Baseline LVEF:
>50%
Patients with cancer and underwent chemotherapy/ Baseline LVEF:
64 (MACE), 68 (No MACE)

Retrospective
observational
study
Prospective blinded
observational
study
Open-label phase
3 randomized
noninferiority trial

Retrospective
observational
study

Inclusion criteria/baseline LVEF & GLS

Study design

Visual/LVEFLVIDLVIS

Breast
cancer

Not Reported/LVEF

New York Heart Association
class III or IV CHF, cardiac
arrest, or cardiac death

Multiple
cancers

Modified Biplane Method and 2D CPA/
LVEFLVEDVLVEDVILVESVLVESVIGLS

NYHA class III or IV CHF,
cardiac arrest, or cardiac
death
Cardiac death and NYHA
class III or IV CHF

Multiple
cancers

Leukemia or
lymphoma

Simpson biplane method/
LVEFLVEDVLVEDVILVESVLVESVIGLSASLS

Symptomatic heart failure or
cardiac death

Type of
cancer

Echocardiogram technique/variables

Primary endpoint

Anthracyclines

Anthracycline + Trastuzumab

Anthracyclines

Anthracyclines

Chemotherapy regimen

10 years

5 years

10 years

4.2 years

Follow-up
duration

ASLS = average segmental longitudinal strain, CHF = congestive heart failure, GLS = global longitudinal strain, LVEDV = left ventricular end diastolic volume, LVEDVI = left ventricular end diastolic volume index, LVEF = left ventricular ejection fraction, LVESV = left ventricular end
systolic volume, LVESVI = left ventricular end systolic volume index, MACE = major adverse cardiovascular events, NYHA = New York Heart Association, PSLS = peak systolic longitudinal strain.

Wang,
2015

Pivot,
2015

Mousavi,
2015

Ali,
2016

Author,
year

Table 1
Summary of included studies.
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Figure 2. Risk of bias summary for the included studies.

GLS and prediction of symptomatic cardiotoxicity (HR 1.46;
95% CI, 1.34–1.58; P ≤ 0.001) (Fig. 4). The I2 value was noted
to be 0, indicating no heterogeneity.

4.2. Baseline left ventricular end diastolic volume

Two studies reported baseline LVEDV.[9,19] Ali et al did not find
any association between LVEDV and subsequent cardiac events
(HR 0.99; 95% CI, 0.98–1.01; P = .580). In contrast, Mousavi et
al found a significant association between LVEDV and symptomatic cardiotoxicity (HR 1.03; 95% CI, 1.01–1.05; P = .012). The
pooled analysis did not identify any significant association (Fig. 5).

4.3. Baseline left ventricular end systolic volume

Two studies reported baseline LVESV, and the results were contrasting.[9,19] Ali et al found LVESV not to be a predictor of cardiotoxicity (HR 1.01; 95% CI, 0.98–1.04; P = .370), whereas
Mousavi et al found LVESV to be associated with the development of symptomatic cardiotoxicity (HR 1.07; 95% CI,
1.02–1.12; P = .0029). The pooled analysis did not identify any
significant association (Fig. 5).

4.3. Baseline left ventricular end diastolic volume index

Two studies reported LVEDVI.[9,19] Ali et al did not find any
association between LVEDVI and occurrence of symptomatic
cardiotoxicity (HR 1.00; 95% CI, 0.97–1.03; P = .910). In contrast, Mousavi et al found LVEDVI to be associated with the
occurrence of symptomatic cardiotoxicity (HR 1.04; 95% CI,

4
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Figure 3. Forest plot for left ventricular ejection fraction as a predictor of symptomatic cardiotoxicity with pooled hazard ratios and study types. The pooled
hazard ratio (HR) with 95% confidence interval (CI) were calculated using a random effects model. Weight refers to the contribution of each study to the pooled
estimate. Squares and horizontal lines denotes the point estimate and 95% CI for each study’s HR. The diamond signifies the pooled HR; the diamond center
denotes the point estimate and the width denotes the 95% CI. CT = cardiotoxicity, OS = observational study, RCT = randomized controlled trial.

Figure 4. Forest plot for global longitudinal strain as a predictor of symptomatic cardiotoxicity with pooled hazard ratios. CT = cardiotoxicity.

1.00–1.09; P = .039). The pooled analysis did not identify any
significant association (Fig. 5).

predictors, given a smaller number of events. There was no indirectness or evidence of publication bias. Studies were heterogeneous as they included patients with variable malignancies,
co-morbidities, and baseline LVEF. Overall, the certainty in the
estimates in all the 5 predictors was judged to be low.

4.4. Baseline left ventricular end systolic volume index
Two studies reported this echocardiographic parameter.[9,19] Ali
et al did not find a significant association between LVESVI and
the occurrence of symptomatic cardiotoxicity (HR 1.05; 95%
CI, 0.99–1.11, P = .058), whereas Mousavi et al found LVESVI
to be associated with the occurrence of symptomatic cardiotoxicity (HR 1.11; 95% CI, 1.02–1.20, P = .012). The pooled analysis did identify a significant association (Fig. 5).

5. Discussion
This systematic review identified LVEF as the most utilized
echocardiographic measure in the literature to predict symptomatic cardiotoxicity. However, it may not be the most accurate. We demonstrate that baseline LVEF is inconsistent in
predicting symptomatic cardiotoxicity in patients undergoing chemotherapy for malignancies. This may partly be due
to the variable loading conditions and physiologic conditions
such as heart rate, blood pressure, anemia, volume status, and
fever that can all influence LVEF. Studies have identified that
applying automated echocardiography techniques using deep
learning algorithms and artificial intelligence can increase the
accuracy of LVEF measurement and improve disease diagnosis.
However, these techniques are not commonly applied in clinical
settings.[21,22] Myocardial deformation indices, particularly GLS,
can detect changes in systolic dysfunction earlier in comparison
with LVEF. Baseline GLS also appears to be a better predictor of
symptomatic cardiotoxicity and overall mortality, as identified
by this meta-analysis. Other echocardiographic parameters such
as LVEDV, LVESV, and LVEDVI have been reported in studies
for predicting symptomatic cardiotoxicity. The results from
these measures of LV dimension have been mixed with no clear
association with symptomatic cardiotoxicity.
We did not find a similar systematic review or meta-analysis performed previously. This is likely due to the scarcity
of data regarding this topic. Oikonomou et al published a

4.5. Other 2D transthoracic echocardiographic parameters
Other echocardiographic parameters examined in association
with symptomatic cardiotoxicity included average segmental longitudinal strain (ASLS), left ventricular internal diameter end diastole (LVID), and left ventricular internal diameter
end-systole (LVIS). Ali et al observed that ASLS had a significant
association with cardiotoxicity development (HR 1.85; 95%
CI, 1.65–2.08, P < .001.[9] Wang et al found LVID and LVIS
to be associated with symptomatic cardiotoxicity (LVID: HR
1.38; 95% CI, 1.08–1.76; P ≤ 0.0001; LVIS: HR 1.50; 95% CI,
1.15–1.95; P = .003).[17]
4.6. Certainty in the estimates
The included studies were observational except for the trial
conducted by Pivot et al with variable methodological quality
resulting in an increased risk of selection and confounding bias.
The estimates were precise for baseline LVEF but not for other
5
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Figure 5. Forest plot for LVEDV, LVESV, LVEDI and LVESVI as a predictor of symptomatic cardiotoxicity showing individual and pooled hazard ratios.
CT = cardiotoxicity, LVEDI = left ventricular end diastolic volume index, LVEDV = left ventricular end diastolic volume, LVESV = left ventricular end systolic
volume, LVESVI = left ventricular end systolic volume index, .

under-investigated to date. Ali et al found that a prechemotherapy GLS value of less than an absolute value of –17.5%
before anthracycline treatment would have correctly identified
24 out of the 28 patients who eventually developed symptomatic cardiotoxicity.[9] Additionally, GLS can predict symptomatic cardiotoxicity in patients with normal LVEF. Similarly,
Mousavi et al prospectively studied a patient population with
normal EF prior to the initiation of anthracycline chemotherapy.[19] GLS was found to be highly predictive of major adverse
cardiac events (MACE), and when GLS was added to any other
clinical variable, the prognostic value increased. Furthermore,
GLS was predictive of symptomatic cardiotoxicity even in
patients with a normal EF (50–59%), highlighting the role of
earlier detection prior to a clinically detectable reduction in
EF.[8] GLS may be more accurate than LVEF since it is measured using automated software with less human interference.
The values are reproducible if the same software is utilized for
measurement.[28,29]
Our meta-analysis did not show a significant association between baseline LVEF and symptomatic cardiotoxicity.
Nevertheless, LVEF is the most utilized echocardiographic measurement to monitor cardiac function in patients undergoing
chemotherapy.[2] Sawaya et al studied the role of LVEF and LV
dimensions in predicting symptomatic cardiotoxicity in patients
receiving chemotherapy with anthracyclines, taxanes, and trastuzumab.[30] It was noted that LVEF measured at the completion
of anthracycline treatment or changes in LVEF between baseline
and completion of anthracycline treatment were not predictive
of later cardiotoxicity. Separately, Mousavi et al prospectively

meta-analysis of the prognostic value of GLS for chemotherapy-related cardiotoxicity but included studies with patients
having both symptomatic and asymptomatic cardiac dysfunction related to chemotherapy.[13] Therefore, a relationship
solely to symptomatic cardiotoxicity could not be ascertained.
Like our study, Oikonomou et al identified that GLS had an
excellent prognostic performance for subsequent chemotherapy-related cardiac dysfunction. Several other studies have
established an association of lower absolute GLS values with
a risk of developing chemotherapy-induced cardiotoxicity,
both before and during treatment.[23–25] Whether or not these
results can be extrapolated to symptomatic cardiotoxicity
remains unclear.
Most of the studies included in this analysis are nonRCTs or
observational studies. Therefore, the scientific evidence is not
of the highest quality. The question of whether echocardiography can predict clinical cardiotoxicity remains challenging.
This is because of the wide variance in the results reported from
observational and randomized trials conducted on this topic.
Furthermore, the American Society of Echocardiography and
the European Society of Cardiovascular Imaging Guidelines
for measuring LVEF using the Simpson volumetric biplane
method are not always employed in LVEF assessment.[26]
Adopting society guidelines and moving to a more accurate
and reproducible 3D LVEF may overcome some of these
challenges.[27]
Our analysis demonstrated that baseline GLS has a significant association with symptomatic cardiotoxicity. The
importance of GLS in predicting cardiotoxicity has been
6
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